MedTech Innovator

APrevent Medical Inc. is a medical device company based in Taipei, Taiwan, with an additional office in Austria. Founded in 2014, the company specializes in developing therapeutic devices aimed at enhancing the quality of life for patients affected by speech disorders. APrevent focuses on creating long-term implant systems and a speech conversion platform, along with other innovative medical equipment. Their offerings include minimally invasive ENT implants and Software-as-a-Service technologies designed to assist in the treatment of voice and communication disorders, enabling patients to improve their speech capabilities effectively.

iCE Neurosystems develops a neuromonitoring platform that focuses on providing early warnings and guiding treatment for patients with brain injuries. By integrating innovative devices, advanced software, and big-data methodologies, the company offers healthcare professionals real-time insights into brain health. This approach allows doctors and nurses to diagnose and prevent brain injuries in critically ill patients, enhancing their ability to deliver timely and effective care.

Prevencio is a developer of multi-proteomic biomarkers designed to revolutionize blood tests for cardiovascular disease. The company's biomarkers employ artificial intelligence to interrogate well-characterized clinical data sets to produce novel, multi-protein, algorithmically-scored tests, enabling clinicians to assess pre-drug/post-drug effects on a composite of heart attack, stroke and cardiac death.

TYBR Health is a medical device company based in Houston, Texas, founded in 2020 by Tim Keane and Alex Smith. The company focuses on developing a sprayable hydrogel designed to protect healing tissues and minimize internal scarring, a common complication following surgical procedures. This innovative hydrogel solution is delivered through a user-friendly device, making it suitable for both open and minimally invasive surgeries. By reducing scarring by 75% in preclinical studies, TYBR's product aims to enhance recovery and improve the healing response of tissues, ultimately benefiting patients who have undergone operations that risk damaging vital internal organs.

Flow Medical specializes in the development of advanced multi-function catheters aimed at diagnosing and treating venous thromboembolic conditions, including pulmonary embolism. Their innovative platform enhances clot visualization and allows for the direct delivery of clot-dissolving medication to the blockage. Additionally, it enables real-time monitoring of treatment progress, empowering clinicians to tailor therapies to individual patient needs effectively. This approach positions Flow Medical as a key player in improving patient outcomes in the management of thromboembolic illnesses.

Acorai is developing a non-invasive heart failure monitoring platform centered on direct intracardiac pressure monitoring (ICPM). The company utilizes a patented combination of sensor technologies and machine learning to provide accurate and cost-efficient heart failure care. This innovative approach allows for non-invasive monitoring of cardiac and pulmonary pressure, which is crucial for improving outcomes in heart failure patients. By analyzing pressure dynamics through acoustic, vibratory, and waveform data, the device enables healthcare professionals to proactively adjust medications, potentially reducing re-hospitalization and mortality rates associated with heart failure. Clinically validated and designated as an FDA Breakthrough Device, Acorai's product is expected to enter the market in 2025.

Qritive is a developer of an AI-powered diagnostic platform that assists medical professionals in analyzing microscopy images and patient data. The platform leverages artificial intelligence and natural language processing to streamline the analysis process, enhancing the efficiency of cancer diagnoses. By providing modern automated tools, Qritive aims to reduce the time and costs associated with cancer diagnosis, ultimately improving healthcare outcomes for patients. The company's innovative approach addresses the challenges faced by doctors in interpreting complex medical information, facilitating quicker and more accurate diagnoses.

Cyted Health specializes in developing a digital diagnostic infrastructure aimed at the early detection of diseases, particularly cancer. By leveraging artificial intelligence and innovative biomarkers, Cyted's platform enhances clinical insights and facilitates improved patient outcomes. The company's mission is to transform diagnostic methodologies, focusing on prevention rather than treatment, thereby contributing to a healthcare landscape where diseases are identified and addressed at their earliest stages.

Today 1 women on 8 has a breast cancer, 40% of them will have a mastectomy to cure cancer and only 14% of them will have reconstruction because actual technics does no fit for breast reconstruction. That’s why LATTICE MEDICAL develops the implantable device MATTISSE which answer to clinical and societal issues and allow women to get back their bodies and life. MATTISSE implant allows a natural reconstruction by regenerating autologous adipose tissues, custom reconstruction thanks to 3D printing and single surgery due to fully biodegradable material, which fully disappear after reconstruction. We aim in long term to replace silicon-based implant by our technology.

Arsenal Medical, Inc. is a technology company based in Watertown, Massachusetts, specializing in the development of polymer-based foams and fibers aimed at treating vascular diseases. Founded in 2005, the company focuses on innovative approaches to local therapy for acute hemorrhage and critical clinical conditions, such as vascular injury and repair. Arsenal Medical's proprietary technologies include in-situ forming foams and AxioCore, a core-sheath nanofiber technology designed for effective cell integration and tissue regeneration. These products utilize safe, non-toxic, and biocompatible materials, allowing for targeted therapeutic delivery in complex anatomical environments. The company is advancing multiple preclinical programs and is backed by venture funding and grants from various organizations, including the Department of Defense and the Bill & Melinda Gates Foundation.

Nurami Medical focuses on creating advanced surgical scaffolds aimed at enhancing the repair and regeneration of soft tissues following internal surgeries. Utilizing electrospinning technology, the company develops biomaterials and nanofiber-based matrices that improve patient outcomes in various surgical procedures. These matrices feature a porous scaffold that promotes tissue regeneration and incorporate a novel temperature-sensitive sealant designed to prevent pathogen entry and cerebrospinal fluid leaks. This innovative approach addresses critical needs in surgical treatment, providing surgeons with effective solutions for their patients.

Aurie is a medical device company based in New York, established in 2018. It focuses on developing a reusable urinary catheterization system aimed at improving the quality of life for individuals with disabilities. By providing a convenient, discreet, and hygienic catheterization option, Aurie seeks to reduce the risk of infections and enhance users' confidence and control over their healthcare needs. The company's innovative approach empowers users to manage their condition more effectively, enabling them to lead active and fulfilling lives.

CytoVeris is a company focused on developing optical-based technologies to assist surgical oncologists in identifying and removing tumor tissue during cancer resection surgeries. Founded in 2018 by Alan Kersey in Farmington, Connecticut, CytoVeris aims to enhance the surgeon's ability to achieve clean margins, thereby improving patient outcomes. The company’s devices facilitate real-time assessment of tissue and generate molecular-specific information by detecting unique signatures created by cancer cells that alter cellular metabolic processes. This includes variations in lipids, proteins, and metabolites, which can be identified using their OncoMap system. By providing oncologists with critical information during surgery, CytoVeris seeks to reduce healthcare costs associated with repeat surgeries.

Astek Diagnostics is focused on developing a precision diagnostic platform that assists physicians in prescribing appropriate antibiotics for patients suffering from bacterial sepsis within one hour. The company’s technology utilizes a single-use cartridge to rapidly detect bacterial infections in urine by measuring the oxygen consumption of various bacterial species. This innovative approach not only speeds up the identification process but also aids in combating antibiotic resistance through effective susceptibility testing.

Craif Inc., previously known as Icaria Inc., is a Tokyo-based company founded in 2018 that specializes in developing innovative devices for early cancer detection through urine tests. The company's flagship product is a MicroRNA device that serves as a biomarker for identifying early-stage cancers. Craif aims to revolutionize cancer diagnosis by providing a method that is painless, accurate, and suitable for regular screening, addressing the critical need for early detection in order to significantly improve survival rates. Traditional cancer diagnostic methods often involve discomfort and lack the precision required for early-stage identification, which can lead to late-stage diagnoses when treatment options are limited. Craif's technology leverages exosome-based liquid biopsy tests that analyze ribonucleic acid, allowing for high sensitivity and specificity in distinguishing cancerous from non-cancerous samples.

AccurKardia is a diagnostics software company specializing in ECG-led technology aimed at enhancing patient outcomes and saving lives worldwide. The company's flagship product, AccurECG™, is a cloud-based, FDA-cleared software that enables fully automated, near real-time interpretation of ECG data. AccurKardia has developed additional solutions, including AK+ Guard™, an AI-driven tool for early detection of hyperkalemia using Lead I ECG data, which has received FDA Breakthrough Device Designation. The company also created the AK-AVS™ model for aortic stenosis detection, which similarly attained Breakthrough Device Designation. AccurKardia's innovative platform combines proprietary artificial intelligence with traditional techniques to deliver clinical-grade ECG analytics, assisting cardiac monitoring companies in analyzing ECGs from various devices. The company has participated in notable accelerator programs, including the 2024 Cohort of MedTech Innovator and the American Heart Association’s Heart and Brain Health Accelerator track, further establishing its commitment to advancing cardiovascular health technology.

Robeaute is a research and development agency that develops neurosurgical microrobots that can adapt to different types of medical evidence.

Promedius, established in 2019, focuses on transforming the approach to aging by developing innovative solutions for the early detection and management of musculoskeletal and metabolic diseases, particularly osteoporosis. The company aims to improve the quality of life and extend healthy lifespans through advanced technology. Its flagship product, PROS® CXR:OSTEO, is a pioneering screening solution that utilizes chest X-ray images to identify individuals at risk of osteoporosis. By employing artificial intelligence in medical imaging, Promedius provides medical professionals with efficient tools to prevent severe fractures among the elderly population, thereby contributing to better health outcomes and enhancing patient care.

BrainSpace collaborates with physicians, families, financial backers, and other parties with the purpose of eliminating the long-term handicap brought on by brain injury.

HealthTech Connex Inc. is a brain technology company situated in the Health and Technology District, dedicated to advancing innovations in translational neuroscience aimed at enhancing health outcomes, particularly in neurological performance. The company focuses on brain vitality and develops technology that assesses cognitive brain health across multiple conditions, including brain injuries and neurological diseases. By bridging the gap between laboratory capabilities and real-world applications, HealthTech Connex enables mental health professionals to identify cognitive impairments early, thereby improving care in both clinical and community settings worldwide.

VinBrain is an artificial intelligence-focused company for health care. They artificial intelligence into medicine and medical image diagnostic. They provide DrAidTM Teleradiology, a remote medical imaging solution, connecting resources and expertise between hospitals to provide patients with quality diagnostic imaging services, anywhere, anytime.

Progressive Neuro, Inc is a Silicon Prairie Center incubated medical device company dedicated to the development of Progressive Stroke Solutions. Progressive Neuro, Inc is focused on developing a unique portfolio of ischemic stroke devices that provide physicians with treatment options beyond aspiration and traditional thrombectomy.

FibriCheck is a medically certified mobile application designed for the screening and monitoring of irregular heart rhythms, particularly atrial fibrillation. As a software-only solution, it allows users to measure their cardiac rhythm simply by placing their finger on their smartphone camera, making it accessible anytime and anywhere. The application automatically shares gathered information with medical professionals, facilitating quicker diagnoses and enabling tailored treatment plans. Additionally, FibriCheck employs an artificial intelligence platform that is device-agnostic, leveraging everyday smartphones and wearables to accurately detect and monitor heart rhythm issues. This innovative approach aims to enhance cardiovascular care by providing users with effective tools to manage their heart health, ultimately improving efficiency and reducing costs associated with cardiovascular treatments.

Invicta Medical is a medical technology company focused on developing innovative treatments for sleep apnea and snoring. Founded in 2013 and based in California, the company has created a wearable neurostimulation device that detects and treats disturbed breathing through electrical stimulation. This device aims to overcome the limitations of traditional therapies, which are often expensive, intrusive, and associated with low patient compliance rates. By providing a smart, comfortable, and cost-effective solution, Invicta Medical seeks to enhance the effectiveness of treatment for sleep disorders and improve patient outcomes.

CancerFree Biotech is a start-up focused on personalized cancer treatment through innovative technologies. The company utilizes circulating tumor cell culture to create organoid systems, which assist healthcare professionals in devising optimal treatment strategies for patients at all stages of cancer. By employing advanced bionic tumor organoid culture systems, CancerFree Biotech aims to minimize the likelihood of ineffective drug use. Their proprietary technology platform, E.V.A., combines organoid culture systems with AI image recognition to efficiently expand circulating tumor cells into cancer-derived organoids for various applications in cancer research, including cell therapy, vaccine development, and new drug discovery. This approach not only enhances the testing of anti-cancer drugs but also alleviates the burden of frequent testing for patients undergoing treatment.

Juniper Biomedical is a medical device company focused on implantable neuromodulation technology aimed at improving pelvic health. The company has developed a micro-implant that provides precision treatment for various pelvic health conditions by modulating distal target nerves locally. This technology specifically stimulates only the target nerves, allowing for less invasive and safer therapeutic options. It addresses a range of issues, including incontinence, sexual dysfunction, and chronic pain, offering patients more effective solutions for managing their health concerns.

IFPx is a company focused on developing innovative patient monitoring technology aimed at improving the management of chronic illnesses, specifically heart failure. Its platform features advanced sensors that measure interstitial fluid pressure, allowing healthcare professionals to directly analyze fluid buildup in patients. This technology aims to enhance the monitoring and treatment of heart conditions, ultimately transforming patient care and outcomes in this critical area of healthcare.

Newrotex is an Oxford-based SME that has developed an off-the-shelf silk-based conduit for the repair of peripheral nerve injuries with IP granted.

Biotome is a biotechnology research firm focused on developing advanced antibody diagnostics aimed at identifying high-risk markers for stomach cancer. The company utilizes next-generation technology and precision immunology to create tests that exceed the capabilities of current antibody screenings, offering enhanced precision and more comprehensive disease information. By improving diagnostic accuracy, Biotome seeks to equip medical professionals with the tools necessary to provide better treatment options for patients, ultimately benefiting healthcare outcomes globally.

AMI Corp specializes in medical consulting and the development of medical devices, focusing on telehealth solutions. The company offers a range of telemedicine services, which include a unique stethoscope system designed for remote auscultation. This innovative technology allows for the transmission of heart sounds as both audible and visual data, facilitating better access to medical care for patients through telehealth initiatives. AMI Corp aims to enhance the delivery of healthcare services by leveraging advanced communication methods in the medical field.

Renovos is an orthopedic regenerative medicine company focused on addressing the growing challenges of bone deterioration due to aging, trauma, and disease. The company develops a range of innovative products and therapeutics that aim to enhance bone healing processes, making them quicker, safer, and more cost-effective. By utilizing advanced stem cell and material technologies, Renovos seeks to meet the unmet needs of researchers and clinicians, ultimately enabling patients to recover more efficiently and alleviate pain associated with bone injuries and conditions.

Sparta Biomedical develops cartilage-like implants for the knee. They specialise in the creation of biomimetic implants that require minimally invasive therapy for chondral or osteochondral knee cartilage abnormalities, providing orthopaedic surgeons with enhancements that fundamentally restore movement for their patients.

INVENIO IMAGING, Inc. is a privately held corporation founded in 2012 based on the research of Prof. Sunney Xie of the Department of Chemistry and Chemical Biology at Harvard University. Invenio is dedicated to developing a fast, reliable, simple-to-use technology for non-destructive microscopic analysis of the molecular make-up of tissues and other materials. INVENIO’s platform technology is positioned to enter the R&D microscopy market, and it is developing instrumentation for several high-value medical applications. INVENIO IMAGING Inc. acknowledges funding from the NSF and NIH SBIR programs.

VeinWay is a medical device company focused on developing innovative solutions for chronic venous occlusions caused by blockages or disease. The firm has created a specialized catheter designed to assist physicians in recanalizing obstructed veins, facilitating the restoration of blood flow to the heart. This platform provides a dedicated tool that enables medical professionals to navigate complex blockages that were previously deemed uncrossable, thereby improving the efficiency and safety of venous treatments. By addressing the challenges associated with chronic venous disease, VeinWay aims to transform the approach to treating these conditions.

MACH32 is a medical device company focused on developing innovative drug delivery solutions to address significant healthcare challenges. The company specializes in creating medical devices designed for the pre-hospital treatment of trauma, producing reliable and functional tools that aim to save lives in urgent situations. Their technology includes novel drug-delivery systems that enable healthcare professionals to utilize protective equipment effectively, safeguarding them from infectious aerosols, particularly highlighted during the Covid-19 pandemic. By prioritizing safety and efficacy, MACH32 addresses critical needs in emergency medical care.

Houston-based medical device startup Prana Thoracic, Inc. is dedicated to developing solutions for early intervention in lung cancer. We are an experienced team of surgeons, engineers and entrepreneurs on a mission to tackle lung cancer; the #1 cancer killer in the US. The paradigm of screening, detection, and early intervention that has been deployed in other major cancers has so far eluded lung cancer. As a result, only 16% of lung cancers are found at an early stage and the current 5-year survival rate is < 20%. Recent changes to lung cancer screening guidelines have illuminated a path to improving outcomes in lung cancer. However, these advances rely on excising suspicious nodules and providing sufficient tissue for definitive diagnosis. We believe this is the missing piece of the puzzle, and physicians need a new generation of surgical oncology tools for lung cancer. Prana Thoracic plans to revolutionize the early diagnosis and treatment of lung cancer by making it easier and less invasive to deal with the rapidly growing number of early suspicious lung nodules; ensuring that we do not miss the window of opportunity to intervene early.

Covellus is a medical device company that is developing a unique Platform Technology for creating medical device catheters.

Xtremedy Medical is a medical technology based at NUI Galway that manufactures surgical devices to treat bone and deep tissue infections by sending electrical signals through wounds, both on the surface and below, to eliminate any residual infection.

Neurava is a company focused on developing non-invasive wearable diagnostic devices for patients with epilepsy, particularly those at risk of Sudden Unexpected Death in Epilepsy (SUDEP). The company's innovative device monitors critical biological signals related to epilepsy, providing timely alerts to caregivers and patients. By offering a reliable monitoring solution, Neurava aims to enhance patient autonomy and deliver peace of mind to families, facilitating timely intervention when necessary. The company's work lies at the intersection of medical device manufacturing and health diagnostics, addressing a significant need within the epilepsy patient community.

Opticyte, Inc. is a medical device company based in Seattle, WA, focused on developing innovative technology for monitoring oxygen levels in cells to prevent organ failure. Founded in 2016 as a spinoff from the University of Washington, Opticyte is creating the first Cell O2 Monitor, a noninvasive oximeter that utilizes advanced algorithms and optical spectroscopy. This device is designed to measure oxygen concentration within cells, facilitating early detection of critical conditions such as shock, sepsis, hemorrhage, and cardiac dysfunction. By enabling clinicians to make timely treatment decisions, Opticyte aims to reduce the risk of multiple organ failure and improve patient outcomes. The company comprises a team with significant expertise in engineering, regulatory affairs, and communications, dedicated to bringing this essential medical technology to market.

Proton Intelligence is a Canadian company, founded in 2020 and based in Vancouver, that specializes in biomarker monitoring to assist in managing chronic diseases and improving patient outcomes. The company has developed a wearable continuous potassium monitoring platform aimed at individuals with hyperkalemia, particularly those suffering from chronic kidney disease and other co-morbidities. By providing accurate and real-time potassium measurements through interstitial fluid analysis, Proton Intelligence facilitates critical health monitoring for both clinicians and patients. This technology enables informed decision-making regarding medications, diet, and treatment options, thereby enhancing the management of hyperkalemia and promoting better overall health for affected individuals.

InterShunt designs and develops a catheter-based minimally-invasive procedure to provide relief for millions suffering from heart failure. It believes that left atrial decompression holds the key to reducing symptoms for those who suffer. It also believes that they can do this using a simple catheter procedure. Most importantly, they believe they can do this without the use of an implant. It was founded in 2015 and is headquartered in St Louis, Missouri.

Perceptive Medical is a developer of medical devices focused on enhancing blood pressure management in critical care settings, specifically in intensive care units (ICUs) and operating rooms. The company's products are designed to integrate seamlessly into modern clinical workflows, providing precision in therapy and addressing inefficiencies in blood pressure management. By enabling measurable improvements in patient care, Perceptive Medical aims to support clinical providers in delivering better outcomes for patients undergoing critical treatment.

PanTher Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative drug-delivery treatments for cancer. The company has created a proprietary platform that enables targeted and sustained drug administration directly at tumor sites, significantly enhancing therapeutic efficacy while minimizing the toxic side effects commonly associated with traditional chemotherapy. This approach allows oncologists to unlock the full potential of cancer drugs, particularly in challenging cases such as pancreatic cancer, where treatment options can be limited. Founded in 2014, PanTher Therapeutics aims to improve cancer care by addressing the needs of patients suffering from life-threatening malignancies.

Xcision Medical Systems, LLC is a medical technology company focused on developing advanced stereotactic radiotherapy solutions, particularly for breast cancer treatment. The company's innovative device utilizes stereotactic gamma irradiation, allowing patients to complete their radiation therapy in a single, noninvasive session, rather than over several weeks. This approach not only significantly reduces the duration of treatment but also minimizes radiation exposure to surrounding healthy tissues, including the lungs and heart. By enhancing the quality of cancer care, Xcision aims to improve patient outcomes and enable individuals to return to their daily lives more quickly and with less discomfort.

Flow Neuroscience AB is a healthcare company based in Malmö, Sweden, focused on developing innovative treatment solutions for depression. Established in 2011, the company creates a wearable device that delivers transcranial direct current stimulation (tDCS) to the forehead, targeting the left frontal lobe, an area often associated with reduced activity in individuals suffering from major depressive disorder (MDD). This headset is complemented by a personalized mobile application designed to encourage users to adopt healthier daily routines, such as improved sleep patterns and increased physical activity. By combining brain stimulation with behavioral therapy, Flow Neuroscience aims to provide a medication-free treatment option that is accessible and affordable, challenging the traditional pharmaceutical approaches to depression. The company aspires to make these effective treatments widely available, moving beyond the confines of specialized clinics.

Endocision is focused on creating innovative minimally-invasive medical devices aimed at enhancing the diagnosis and treatment of lung diseases. The company specializes in technologies compatible with bronchoscopy and robotic bronchoscopy, offering solutions that include a cryo-biopsy platform. These advancements enable healthcare professionals to effectively diagnose and manage conditions such as interstitial lung disease and lung cancer. By prioritizing safety and efficacy, Endocision seeks to improve patient outcomes in the field of pulmonary medicine.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, that specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. Founded in 2019, the company offers the world's first brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation to provide adaptive and personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. Its technology enables continuous real-time monitoring and autonomous adjustments to therapy, enhancing therapeutic outcomes while reducing side effects. INBRAIN is also engaged in strategic collaborations, including with Merck KGaA, to expand its innovative solutions into peripheral nerve and systemic disease applications, thereby advancing the field of neurotechnology and bioelectronics.

Hypervision Surgical focuses on enhancing surgical precision, safety, and efficiency through its innovative imaging technology. The company develops an advanced non-contact and non-invasive optical imaging system that employs hyperspectral imaging to analyze tissues during surgery. By splitting light into multiple spectral bands, the system provides real-time, data-driven tissue characterization, allowing clinicians to visualize and assess tissue without the need for contrast agents. This technology aims to improve surgical outcomes while minimizing risks to patients, positioning Hypervision Surgical at the forefront of AI-powered surgical assistance.

ImmersiveTouch, Inc. is a medical technology company based in Chicago, Illinois, specializing in virtual reality simulators for medical training and patient engagement. Established in 2005, the company develops applications for surgical education and pre-operative planning, utilizing its advanced Ikshana XR platform. This platform employs proprietary software and artificial intelligence to convert radiology scans into 3D simulations, allowing for detailed anatomical exploration and informed surgical decision-making. ImmersiveTouch's surgical simulators feature an immersive pod where surgeons interact with realistic 3D models, experiencing high visual acuity and realistic sensory feedback. The training modules cover various specialties, including core surgical skills, neurosurgery, orthopedic surgery, spine, and ophthalmology. By providing actionable insights, ImmersiveTouch aims to improve patient outcomes, reduce complications, and enhance the efficiency of surgical procedures.

Universal Brain is focused on creating individualized treatments for mental health by utilizing advanced neurofeedback therapy methods. The company engages in research and development of algorithms that integrate data from electroencephalograms (EEG) and magnetic resonance imaging (MRI) through deep learning techniques. This approach allows for the design and manufacturing of portable electroencephalograph headsets, enhancing the capabilities of mental health professionals in diagnosing and treating psychiatric conditions. By analyzing brain data, Universal Brain aims to provide valuable insights that improve the effectiveness of psychiatric care.

Newrotex is an Oxford-based SME that has developed an off-the-shelf silk-based conduit for the repair of peripheral nerve injuries with IP granted.

Pumpinheart is a heart failure treatment system with preserved ejection fraction (HFpEF).

Averto Medical is a manufacturer of medical devices focused on addressing gastrointestinal diseases. The company specializes in developing innovative solutions designed to facilitate minimally invasive colorectal tumor removal, which aims to reduce the need for multiple surgical procedures and associated complications. By providing effective medical care options for patients suffering from gastrointestinal disorders, Averto Medical seeks to improve patient outcomes and streamline treatment processes in this critical area of healthcare.

Knowtex provides savings in administrative work, streamlines organisational efficiency, ensures visits are billed at the appropriate level of service, and has personable conversations with patients. It helps create visit notes from medical conversations. For inquiries, an online inquiry form is available on their website.

270Surgical Ltd. is a medical device company based in Netanya, Israel, founded in 2016. It specializes in the development of the SurroundScope System, an innovative laparoscopic camera designed to enhance visualization during surgery. This system features a unique 270-degree wide field of view technology, which significantly reduces blind spots and the risk of off-screen injuries, thereby improving patient outcomes. The SurroundScope also addresses common issues faced during laparoscopic procedures, such as lens fogging and visual obstructions from surgical smoke. The system has received FDA clearance and has garnered endorsements from leading experts in the field, positioning 270Surgical as a key player in advancing surgical techniques.

Purgo Scientific is a medical device company focused on developing an innovative drug delivery system aimed at addressing the challenges posed by biofilm infections in orthopedic surgery. The company's technology is designed to create a sustainable, localized delivery method that targets therapeutic drugs directly to the site of infection, thereby treating and preventing biofilm-related surgical site infections that can affect orthopedic implants. This approach not only aims to eradicate infections caused by biofilms but also has potential applications in managing various health issues that benefit from precise medicine delivery, including pain management and oncology.

Ankr Health uses AI and telemedicine to automate side effect management in cancer and surgical clinics. Founded in 2022 and is based in San Francisco, CA.

Hertility Health is a women's health company focused on reproductive and hormonal health. It aims to reshape the landscape of reproductive healthcare by offering innovative diagnostic testing that delivers insights into reproductive health, fertility decline, and menopause. Hertility enables women to understand their symptoms through community-based home testing and evidence-based medical guidance. The company provides educational resources and access to expert advice, allowing women to visualize their biological clock and reproductive biology. This approach empowers women with actionable insights and pathways to care, all from the comfort of their homes.

Nininger Medical is focused on developing a transcatheter tricuspid valve replacement device (TTVR) that utilizes proprietary 3D thin film technology. This innovative approach aims to provide effective treatment for heart failure, particularly in preventing structural heart issues. The company has recently received a Small Business Innovation Research grant from the National Science Foundation, underscoring its commitment to advancing medical technology in the field of cardiovascular care.

CardieX is a global health technology company that focuses on hypertension, cardiovascular disease, and other vascular health disorders.

EchoPixel, Inc. develops medical imaging devices. The company develops a non-invasive colon cancer screening solution that enables doctors and radiologists to use computed tomography (CT) images of a patient’s abdomen and display a 3D model of a patient’s colon. With this tool, any medical professional can examine the entire colon by using a navigate and detect approach to identify most polyps or other abnormalities, the cause of cancer. The company was incorporated in 2012 and is based in San Jose, California.

Travera, LLC is a biotechnology company based in Cambridge, Massachusetts, founded in 2017. It specializes in a unique measurement technology that utilizes the Suspended Microchannel Resonator (SMR), a MEMS device capable of detecting minute changes in the weight of individual cancer cells. This technology focuses on the Mass Accumulation Rate (MAR) biomarker, which indicates how cancer cells respond to various drugs within hours of exposure. By measuring these rapid changes, Travera enables oncologists to make informed decisions about which therapies to prescribe based on the actual responses of a patient’s tumor cells. This approach aims to enhance the effectiveness of cancer treatment by distinguishing between natural cell death and drug-induced cell death, thereby improving patient outcomes.

4th Dimension EMR develops electronic health record (EHR) software aimed at assisting healthcare practitioners in managing patient information and documentation. The company offers a cloud-based platform that enhances practice management by streamlining scheduling and ensuring that medical records are accessible anytime and anywhere. This software is designed to improve workflow efficiency for medical practices, allowing practitioners to focus more on patient care while effectively maintaining comprehensive records.

NXgenPort Inc focuses on enhancing cancer care through its innovative digital health technology, which includes an implanted Smart Port for remote patient monitoring between chemotherapy sessions. This system measures vital health metrics, such as cell counts and heart function, allowing for timely alerts to physicians regarding potential infections. By reducing hospitalizations and collecting critical physiological data, NXgenPort aims to improve overall patient outcomes. Additionally, the technology offers significant advantages for cancer researchers and drug delivery stakeholders by enabling them to remotely assess a participant's biological response to various interventions, thereby supporting more effective treatment strategies.

SafeGuard Surgical provides much-needed products that will ensure safer surgery for better patient outcomes while lowering costs, preventing additional surgical interventions, and reducing patient length of stay, but most importantly, preventing mortality and morbidity, which is an all-too-common risk of surgery.

Mirai Medical is a medical device company focused on developing innovative technologies for cancer therapy. Its unique intellectual property allows for the painless delivery of electroporation energy through endoscopic procedures, significantly improving the treatment of cancer. This technology enables endoscopists to perform pulse field ablation safely and efficiently, ultimately aiming to enhance patient outcomes and experiences in cancer treatment.

DasiSimulations is a company that specializes in providing innovative simulations aimed at enhancing pre-operative preparation for patients with heart disease, particularly those suffering from Structural Heart Disease. Founded in 2019 by Teri Anderson-Sirset and Dr. Dasi, and headquartered in Dublin, Ohio, DasiSimulations focuses on improving patient outcomes and reducing healthcare costs through advanced individualized computational predictive modeling. Utilizing artificial intelligence and proprietary algorithms, the company's technology platform empowers medical professionals to make more informed decisions during transcatheter aortic valve replacement procedures.

Sentante is a medical device company focused on developing robotic teleoperated systems specifically for endovascular procedures. By utilizing this innovative technology, Sentante enables physicians to perform surgeries remotely, significantly reducing their exposure to harmful X-rays. The company has designed a manipulator that assists endovascular practitioners in conducting procedures with minimal radiation risk, promoting safer practices in the medical field. Additionally, Sentante's robotic systems facilitate minimally invasive coronary procedures, enhancing the ability of surgeons to carry out complex endovascular surgeries while also contributing to a decrease in oncological diseases among healthcare personnel.

Fluid Biomed is a medical device start-up dedicated to the development of an innovative implantable dissolving stent specifically designed for the treatment of brain aneurysms. Founded by a team of neurosurgeons, the company aims to enhance patient outcomes by offering a bio-absorbable polymer-based flow-diverting stent that promotes healing and minimizes the need for invasive surgical procedures. This revolutionary device gently redirects blood flow to facilitate the healing of weakened aneurysms, enabling physicians to treat patients efficiently and effectively while reducing the risk of complications such as stroke.

Gradient Denervation Technologies is a Paris-based company founded in 2019 that focuses on the development of an endovascular catheter-based medical device designed to treat pulmonary hypertension. This innovative technology aims to reduce pulmonary vascular resistance and enhance cardiovascular hemodynamics through a minimally invasive procedure. The device is built on prior research and intellectual property developed at Stanford University and offers a novel approach to pulmonary artery denervation, addressing heart failure and associated pulmonary hypertension. By providing a reliable and effective treatment option, the company seeks to improve patient outcomes in the healthcare industry.

Epineuron is a bioelectronic medicine company bringing a new standard of care for peripheral nerve repair and regeneration. The company is developing a suite of surgical solutions for repairing and treating peripheral nerve injuries with the mission of becoming the world leader in bioelectronic nerve care, starting with its neuroregenerative therapy.

MicroGEM is a microbiology research company focused on democratizing molecular biology by transferring complex molecular biology techniques from specialized laboratories to non-laboratory environments. The company employs an innovative enzymatic method for nucleic acid extraction, which facilitates sample preparation compatible with PCR (polymerase chain reaction) analysis. This technology supports the development of portable diagnostic devices aimed at managing infectious diseases and enhancing personalized medicine applications, making advanced molecular biology accessible to a broader audience.

Healthcare X.0 is an online healthcare platform that provides its clients with digitization solutions. The platform provides its clients with health, vascular, patient, onco, nephro, cardio, wound, tele, patient, and diabetic assist database solutions. Healthcare X.0 was launched in 2013 by and is based in Niedersachsen.

MeaCor Inc., based in Montreal, Canada, specializes in the development of innovative transcatheter devices designed to address heart disease, particularly valvular conditions. The company manufactures a catheter-based medical device aimed at repairing the mitral and tricuspid valves, utilizing an anchoring catheter system to facilitate these procedures. This technology focuses on transcatheter interventions that minimize the risks and trauma typically associated with conventional surgical methods. By doing so, MeaCor enables effective treatment for patients who are not candidates for traditional surgery, specifically targeting those suffering from mitral valve regurgitation.

SUTUREGARD Medical, Inc. is a medical device company based in Portland, Oregon, specializing in the development and manufacture of innovative wound closure devices. The company offers products designed to simplify surgical procedures and improve patient outcomes. Notably, the SUTUREGARD ISR device facilitates stress-relaxation in suture applications, effectively addressing issues related to skin stretch and tension in surgical wounds. Additionally, the HEMIGARD ARS is an adhesive retention suture device that enhances skin strength, allowing for linear wound closure while minimizing the risk of skin tearing. Founded in 2014, SUTUREGARD Medical aims to provide solutions that enable painless wound healing, particularly for high-tension and fragile skin wounds, thereby reducing damage compared to traditional suturing methods.

Moon Surgical is a medical device company focused on enhancing laparoscopic surgery through its innovative Maestro System. This system is designed to facilitate access to minimally invasive surgical techniques while optimizing resource utilization in the operating room. By providing features such as stabilization and automatic positioning of endoscopes, along with organ retraction, the Maestro System aims to improve surgical efficiency and patient care. Moon Surgical's technology allows surgeons to maintain their existing workflows and techniques, integrating the advantages of robotic assistance without disrupting traditional practices. Through its commitment to advancing surgical technology, Moon Surgical seeks to transform the landscape of surgery today.

Garwood Medical Devices, LLC is a Buffalo, New York-based company that specializes in developing and manufacturing medical devices focused on infection management, particularly related to prosthetic implants and wound healing. The company's flagship product, BioPrax, is a minimally invasive device designed to target and eliminate biofilm infections on prosthetic knee implants during early intervention procedures. This innovative approach allows medical practitioners to effectively treat implant infections without the need for follow-up surgeries, thereby enabling patients to retain their implants. Founded in 2014 and initially known as Enermed, LLC, the company adopted its current name in December 2015, reflecting its commitment to advancing medical technology in infection control.

Bright Uro is an early-stage medical technology company focused on developing innovative diagnostic devices for urology. The company has created a glean urodynamics system that combines advanced hardware, software, and data science to deliver wireless, catheter-free urodynamics. This system aims to enhance the accuracy and comfort of urological assessments, ultimately transforming the standard of care for patients with lower urinary tract symptoms and diseases. By providing actionable insights, Bright Uro empowers clinicians to improve patient outcomes and streamline the treatment process.

Aqua Medical, Inc. is focused on developing innovative, vapor-based, endoscopic ablation technology aimed at treating gastrointestinal diseases and preventing gastrointestinal cancers. Founded in 2016 and based in Santa Ana, California, the company utilizes high-temperature water vapor generated by a radiofrequency generator. This vapor is delivered endoscopically through proprietary catheters, allowing for a minimally invasive approach to treat various conditions within the gastrointestinal tract, including pancreatic cysts and esophageal issues. Aqua Medical's platform technology offers a convenient and effective alternative to traditional surgical methods, enhancing treatment options for medical practitioners and their patients.

CardiaCare is a developer of a wearable medical device aimed at the non-invasive treatment and monitoring of atrial fibrillation (AFib) in patients at home. The device employs a closed-loop approach and machine learning algorithms to deliver personalized peripheral neuromodulation therapy. This innovative technology mediates a cardiovascular antiarrhythmic response, helping users to alleviate the burden of atrial fibrillation and address precursors such as premature atrial contractions. As a result, CardiaCare’s device offers users the potential for rapid clinical and symptomatic relief.

SafeBeat Rx specializes in advanced electrocardiogram technology that enhances cardiac monitoring by allowing patients to manage their care remotely. The company's software facilitates remote patient monitoring, continuous telemetry, and event monitoring, thus eliminating the need for prolonged hospital stays. SafeBeat Rx's solutions are particularly beneficial for arrhythmia patients, as they enable safe initiation of medications and ongoing management from home. Powered by automated artificial intelligence, their technology also supports the monitoring of cardiac implantable electronic devices, making cardiac care more accessible and efficient for patients.

Liquet Medical is a medical device development company that transforms the way the vascular disease is treated through localized drug delivery. The Versus Catheter will be Liquet Medical’s first technology to market.

Augment Health focuses on enhancing the management of bladder dysfunction, particularly for the 7 million patients affected by neurological diseases or injuries. The company is developing a noninvasive bladder monitor along with an AI algorithm that allows for home diagnostics, addressing the high rate of inconclusive results seen in clinical settings. By shifting bladder health monitoring out of the clinic, Augment Health's technology aims to prevent complications such as bladder muscle atrophy by notifying patients or caregivers when the catheter is full, thus promoting better bladder health management. This innovation targets a significant market valued at $12.3 billion, providing a practical solution to improve the quality of life for individuals facing bladder dysfunction.

SymPhysis Medical's goal is to develop innovative technologies that treat a range of chronic diseases, putting the patient experience at the forefront of our design solutions to improve quality of life. About SymPhysis MedicalSymPhysis Medical's emergent technology, releaze, is a drainage technology to treat a common complication of late-stage cancers, malignant pleural effusion (MPE). MPE causes significant shortness of breath and chest pain in up to 15% of patients with cancer.

Oxford Endovascular is focused on developing an innovative medical device for the treatment of brain aneurysms. The company's technology employs a laser-cut metal alloy with shape-memory properties, which can be inserted into a patient's brain via a catheter. Once in place, the device expands into a tiny mesh tube, known as a flow diverter, that conforms to the natural shape of the blood vessel. This design effectively diverts blood flow away from the aneurysm, facilitating its healing and reducing the risk of rupture. By utilizing advanced origami engineering, Oxford Endovascular aims to enhance patient outcomes and improve survival rates for those affected by intracranial aneurysms.

Phagenesis is developing a device for the treatment for dysphagia, the inability to swallow safely, that often accompanies stroke or other neuro-deficit diseases. The approach is to harness the brain's own capacity for relearning functions that have been lost through brain damage (via "neuroplasticity" or "cortical remapping"). Focusing initially on the care of stroke patients as they recover in hospital (acute care), Prof Shaheen Hamdy of the University of Manchester, UK, painstakingly devised a method of delivering electrical signals from the pharynx (throat) along nerve cells directly to the relevant parts of the brain. The results of his work have been published in top peer-reviewed scientific and medical journals, including The Lancet, the Nature group of publications, and Gastroenterology.

Endoron Medical specializes in the development of medical devices aimed at improving the treatment of abdominal aortic aneurysms. The company focuses on creating an endovascular suture device that enhances the effectiveness of endovascular aneurysm repair procedures. By designing long-lasting sealing equipment for endografts, Endoron Medical provides healthcare professionals with advanced technology to treat patients more effectively. This innovation is intended to improve patient outcomes and streamline surgical processes in the management of abdominal aortic aneurysms.

Anumana develops advanced AI algorithms that analyze electrocardiogram (ECG) data to facilitate early diagnosis of cardiovascular conditions. The company focuses on enhancing cardiac care through innovative technology, providing healthcare professionals with tools to identify potential heart issues more effectively. Anumana's platform supports not only diagnostics but also aims to improve patient outcomes across the entire spectrum of cardiovascular care, including perioperative and acute settings. By employing machine learning techniques, Anumana seeks to refine screening processes, enabling clinicians to detect heart diseases and intervene promptly. This approach enhances healthcare delivery and promotes better management of cardiovascular health.

ConKay Medical Systems is an early-stage medical device company advancing solutions to treat valvular regurgitation in patients with progressive heart failure.

Flosonics Medical is a medical device company based in Sudbury, Canada, founded in 2017. It specializes in the development of non-invasive sensors aimed at enhancing the management of critically ill patients. The company's flagship product, the FloPatch, is a wearable sensor designed to monitor blood flow in patients' necks following clinical interventions. This innovative device addresses critical clinical needs for healthcare professionals, including physicians, nurses, and paramedics, working in various settings such as ambulances, emergency departments, operating rooms, and intensive care units. By integrating wearable ultrasound technology with connected devices, Flosonics Medical provides portable and user-friendly solutions that facilitate hands-free operation and improve patient care.

Forest Devices, Inc. is a medical device company based in Pittsburgh, Pennsylvania, with an additional office in Canada. Founded in 2014, the company focuses on developing innovative solutions for stroke detection. Its primary product, AlphaStroke, is a portable and non-invasive stroke screening device that assists medical personnel in identifying early signs of both ischemic and hemorrhagic strokes. This device is designed to be low-cost and durable, enabling pre-hospital providers to triage patients effectively and make timely decisions regarding their care. By improving the speed and accuracy of stroke detection, Forest Devices aims to reduce delays in critical treatment for patients experiencing strokes.

OncoRes Medical is an early-stage medical device company based in Perth, Western Australia, focused on developing an innovative imaging technology that enhances intraoperative surgical procedures. This technology, which employs a novel combination of optical coherence tomography, aims to improve surgical accuracy and reduce complication rates during breast cancer surgeries by providing real-time information that helps surgeons distinguish between tumor and healthy tissue. In collaboration with leading researchers from the University of Western Australia and the Harry Perkins Institute of Medical Research, as well as breast cancer surgeons within the Western Australian public health system, OncoRes Medical is advancing its patent-protected technology. The company is supported by funding from the Medical Research Commercialisation Fund, with the goal of transforming the standard of care in clinical applications that require detailed assessment of tissue microstructure.

Orbit Genomics is a company focused on developing a genomics platform aimed at the early detection, treatment, and prevention of complex diseases. Their proprietary technology analyzes repetitive DNA, which provides insights into both inherited and acquired disease risks. By examining different aspects of deoxyribonucleic acid, the platform enables healthcare professionals to enhance precision medicine through the creation of clinically actionable tests. This approach supports physicians in identifying disease predispositions and developing targeted interventions, ultimately aiming to improve patient outcomes.

Moving Analytics is a telehealth service provider that specializes in cardiovascular prevention programs. Its first product Movn is an end-to-end, integrated program to deliver remote and virtual cardiac rehab. The platform reduces readmissions and empowers the effective and efficient delivery of quality care to patients based on 30+ years of research in remote disease management from Stanford University.

Our founding team consists of highly experienced engineers with a strong record of successful technical projects from inception through production. As a founding principle, we have decided to apply the lessons and talents acquired after many decades to accomplish Evergaze's highly humanistic mission. Even though much of our technical knowledge is derived from the commercial, industrial and defense industries, it is all coming together to achieve this technologically breakthrough product that would not otherwise be possible. seeBoost® is the result of extensive consultation with a variety of stakeholders in low vision, including patients, practitioners, and researchers.

ATRO Medical B.V., based in Nijmegen, the Netherlands, focuses on developing innovative solutions for knee joint health through its anatomically shaped meniscus implant, the Trammpolin. This implant is designed to restore the protective function of the meniscus by acting as a joint spacer, thus alleviating pain and improving life quality for patients suffering from osteoarthritis. The company emerged as a spin-out from DSM and Radboudumc, leveraging insights gained from a collaborative initiative that began in 2010, involving various universities and private enterprises with support from the Dutch government. The Trammpolin prosthesis is a synthetic, non-resorbable substitute that mimics the natural meniscus, functioning effectively as a shock absorber by ensuring adequate load distribution within the knee joint.

CoapTech, Inc. is a medical device company based in Baltimore, Maryland, specializing in ultrasound-based solutions for the placement of feeding tubes. Founded in 2016, CoapTech has developed the Point-of-care Ultrasound Magnet Aligned (PUMA-G) System, which mitigates risks associated with traditional methods such as PEG blind sticks, endoscope reprocessing, and fluoroscopy by allowing for ultrasound visualization from the stomach wall to the surface. The company also offers a procedure known as Percutaneous Ultrasound Gastrostomy (PUG), designed for critical care physicians and non-surgical providers to simplify the insertion of gastrostomy tubes. Utilizing a proprietary technology called Coaptive Ultrasound, CoapTech combines magnetic device guidance with real-time ultrasound feedback, aiming to improve safety, reduce healthcare costs, and enhance patient care experiences. Their focus on the PUG procedure highlights a commitment to innovation, safety, and accessibility in medical care delivery across various patient populations.

Subtle Medical, Inc. is a healthcare technology company based in Menlo Park, California, that specializes in developing AI-powered medical imaging software for clinical imaging centers and hospitals. Founded in 2017, the company offers products such as SubtleMR and SubtlePET, both of which are FDA cleared and CE marked. These technologies enhance image quality in magnetic resonance imaging (MRI) and positron emission tomography (PET) exams by reducing noise and increasing sharpness, ultimately improving workflow efficiency while ensuring patient safety. Subtle Medical also features SubtleGAD, a technology recognized by the Radiological Society of North America, which aims to make imaging exams safer. The company employs a vendor-agnostic AI infrastructure that integrates seamlessly with existing scanners, allowing imaging providers to serve more patients effectively by enhancing image acquisition without disrupting their current workflow. Through its innovations, Subtle Medical seeks to improve the quality, value, and accessibility of medical imaging while significantly lowering costs and radiation exposure.

toSense, Inc. is a healthcare technology company based in San Diego, California, focused on developing innovative solutions for at-home monitoring of chronic illnesses, particularly for patients with conditions such as congestive heart failure and chronic obstructive pulmonary disease. The company's flagship product, the CoVa Monitoring System, is a wearable sensor designed to monitor various health parameters, including thoracic impedance, heart rate, and respiration rate. This device, worn as a necklace and secured with disposable electrodes, transmits vital signs to gateways that relay the data to a web-based system for clinical review. This technology allows healthcare providers to detect potential issues earlier than traditional monitoring methods, enabling timely intervention. Established in 2008 and formerly known as Perminova, Inc., toSense operates as a subsidiary of Baxter International Inc. and aims to address pressing medical challenges through its hardware and software solutions.